Literature DB >> 31962283

Known fentanyl use among clients of harm reduction sites in British Columbia, Canada.

Mohammad Karamouzian1, Kristi Papamihali2, Brittany Graham2, Alexis Crabtree3, Christopher Mill2, Margot Kuo2, Sara Young2, Jane A Buxton4.   

Abstract

BACKGROUND: North America is in the midst of an opioid overdose epidemic and it is commonly suggested that exposure to fentanyl is unknown. Using a provincial survey of harm reduction site clients, we aimed to characterize known and unknown fentanyl use and their correlates among people who use drugs in British Columbia, Canada.
METHODS: We recruited 486 clients who were >18 years old and 316 agreed to provide a urine sample for substance use testing. Reported known fentanyl use was defined as a three-level categorical variable assessing recent (i.e., in the previous three days) fentanyl exposure: (i) known exposure; (ii) unknown exposure; and (iii) no exposure. We also assessed any exposure to fentanyl (Yes vs. No) confirmed by urinalysis. Survey data were summarized using descriptive statistics. Multinomial logistic regression and modified Poisson regression models were built to examine different correlates of exposure to fentanyl.
RESULTS: Median age of the participants was 40 (IQR: 32-49). Out of the 303 eligible participants, 38.7% (117) reported known fentanyl use, 21.7% (66) had unknown fentanyl use, and 39.6% (120) had no recent fentanyl use. In the adjusted multinomial logistic regression model and in comparison with unknown fentanyl use, recent known fentanyl use was significantly associated with self-report of methadone use (aRRR = 3.18), heroin/morphine use (aRRR = 4.40), and crystal meth use (aRRR = 2.95). Moreover, any recent exposure to fentanyl (i.e., positive urine test for fentanyl) was significantly associated with living in urban settings (aPR = 1.49), and self-reporting recent cannabis use (aPR = 0.73), crystal meth (aPR = 1.45), and heroin/morphine use (aPR = 2.48).
CONCLUSION: The landscape of illicit opioid use is changing in BC and more people are using fentanyl knowingly. The increasing prevalence of known fentanyl use is concerning and calls for further investments in public awareness and public policy efforts regarding fentanyl exposure and risks.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Canada; Fentanyl; Opioids; Overdose; People who use drugs; Substance use disorder

Mesh:

Substances:

Year:  2020        PMID: 31962283     DOI: 10.1016/j.drugpo.2020.102665

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  16 in total

Review 1.  Patterns and motivations of polysubstance use: a rapid review of the qualitative evidence.

Authors:  Michèle Boileau-Falardeau; Gisèle Contreras; Geneviève Gariépy; Claudie Laprise
Journal:  Health Promot Chronic Dis Prev Can       Date:  2022-02       Impact factor: 3.240

2.  Evaluating the population-level effects of overdose prevention sites and supervised consumption sites in British Columbia, Canada: Controlled interrupted time series.

Authors:  Dimitra Panagiotoglou
Journal:  PLoS One       Date:  2022-03-22       Impact factor: 3.240

3.  Prevalence and longitudinal correlates of recent exposure to fentanyl among HIV-positive people who use unregulated drugs during a community-wide overdose crisis.

Authors:  Soroush Moallef; Ekaterina Nosova; Seonaid Nolan; Nadia Fairbairn; Jane Loh; Kanna Hayashi; M-J Milloy
Journal:  AIDS Care       Date:  2021-03-25

4.  Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada.

Authors:  Samantha Young; Kanna Hayashi; Cameron Grant; M J Milloy; Kora DeBeck; Evan Wood; Nadia Fairbairn
Journal:  Drug Alcohol Depend       Date:  2021-08-28       Impact factor: 4.492

Review 5.  Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction.

Authors:  Christopher M Jones; Debra Houry; Beth Han; Grant Baldwin; Alana Vivolo-Kantor; Wilson M Compton
Journal:  Ann N Y Acad Sci       Date:  2021-09-24       Impact factor: 6.499

6.  Awareness of fentanyl exposure and the associated overdose risks among people who inject drugs in a Canadian setting.

Authors:  Kanna Hayashi; Evan Wood; Huiru Dong; Jane A Buxton; Nadia Fairbairn; Kora DeBeck; M-J Milloy; Thomas Kerr
Journal:  Drug Alcohol Rev       Date:  2021-02-18

7.  The Evolving Overdose Epidemic: Synthetic Opioids and Rising Stimulant-Related Harms.

Authors:  Christopher M Jones; Faraah Bekheet; Ju Nyeong Park; G Caleb Alexander
Journal:  Epidemiol Rev       Date:  2020-01-31       Impact factor: 4.280

8.  The Increasing Prevalence of Fentanyl: A Urinalysis-Based Study Among Individuals With Opioid Use Disorder in New York City.

Authors:  Suky Martinez; Jermaine D Jones; Laura Brandt; Aimee N C Campbell; Rebecca Abbott; Sandra D Comer
Journal:  Am J Addict       Date:  2020-08-10

9.  The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study.

Authors:  Sofia R Bartlett; Stanley Wong; Amanda Yu; Margo Pearce; Julia MacIsaac; Susan Nouch; Prince Adu; James Wilton; Hasina Samji; Emilia Clementi; Hector Velasquez; Dahn Jeong; Mawuena Binka; Maria Alvarez; Jason Wong; Jane Buxton; Mel Krajden; Naveed Z Janjua
Journal:  Clin Infect Dis       Date:  2022-03-01       Impact factor: 20.999

10.  Public health messaging and harm reduction in the time of COVID-19.

Authors:  Mohammad Karamouzian; Cheyenne Johnson; Thomas Kerr
Journal:  Lancet Psychiatry       Date:  2020-05       Impact factor: 77.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.